Myocarditis has been observed as a rare adverse effect after mRNA COVID-19 vaccination, particularly in young males after the second dose.
The incidence is highest in adolescent and young adult males, with rates such as 8.09 cases per 100,000 after the second dose in males, and much lower in females.
With rise in new cases Should AEFI reporting mechanism be strengthened in health sector . Any suggestions?